| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5998427 | WOODWARD | Androstenones |
Sep, 2013
(10 years ago) | |
| US5846976 | WOODWARD | Androstenone derivative |
Sep, 2013
(10 years ago) | |
| US5565467 | WOODWARD | Androstenone derivative |
Nov, 2015
(8 years ago) | |
Jalyn is owned by Woodward.
Jalyn contains Dutasteride; Tamsulosin Hydrochloride.
Jalyn has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Jalyn are:
- US5998427
- US5846976
- US5565467
Jalyn was authorised for market use on 14 June, 2010.
Jalyn is available in capsule;oral dosage forms.
Jalyn can be used as method of treating androgen responsive or medicated condition in a mammal by administering a safe & effective amount of dutasteride or a pharmaceutically acceptable solvate thereof.. conditions include benign prostatic hypertrophy, method of treating an androgen response or mediated disease in a mammal by administering an effective androgen responsive or medicated disease amount of dutasteride..conditions include benign prostatic hyperplasia.
The generics of Jalyn are possible to be released after 20 November, 2015.
Drugs and Companies using DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE ingredient
Market Authorisation Date: 14 June, 2010
Treatment: Method of treating an androgen response or mediated disease in a mammal by administering an effective androgen responsive or medicated disease amount of dutasteride..conditions include benign prostati...
Dosage: CAPSULE;ORAL
JALYN family patents
